Navigation Links
Targeting downstream proteins in cancer-causing pathway shows promise in cell, animal model
Date:11/13/2012

PHILADELPHIA - The cancer-causing form of the gene Myc alters the metabolism of mitochondria, the cell's powerhouse, making it dependent on the amino acid glutamine for survival. In fact, 40 percent of all "hard-to-treat" cancers have a mutation in the Myc gene.

Accordingly, depriving cells of glutamine selectively induces programmed cell death in cells overexpressing mutant Myc.

Using Myc-active neuroblastoma cancer cells, a team led by Howard Hughes Medical Institute (HHMI) investigator M. Celeste Simon, Ph.D., scientific director for the Abramson Family Cancer Research Institute (AFCRI), identified the proteins PUMA, NOXA, and TRB3 as executors of the glutamine-starved cells. These three proteins represent a downstream target in the Myc pathway at which to aim drugs. Roughly 25 percent of all neuroblastoma cases are associated with Myc-active cells.

The findings appear in this week's issue of Cancer Cell. Simon is also a professor of Cell and Developmental Biology at the Perelman School of Medicine, University of Pennsylvania. The Penn team collaborated with colleagues from The Children's Hospital of Philadelphia (CHOP) John Maris and Michael Hogarty.

"These findings come from studies of fundamental cellular pathways and would not have been discovered without ongoing support for basic research," notes Simon. "Translational research is very important, but equal emphasis on basic research of processes such as cellular metabolism is critical for the ultimate cure of cancer."

Glutamine depletion in Myc-mutant cells induces cell death through a complicated series of molecular switches involving the three protein executors and the DNA-binding protein ATF4. Knowing this, the team showed that either agonists of ATF4 or inhibitors of glutamine metabolism potently caused cell death in assays using neuroblastoma cells and inhibited tumor growth in transgenic mice. Drugs in these two classes have been approved by the Food and Drug Administration and are being tested in clinical trials for other disorders.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Targeting inflammation to treat depression
2. Targeting inflammation to prevent, treat cancers
3. New targeting technology improves outcomes for patients with atrial fibrillation
4. IBN discovers human neural stem cells with tumor targeting ability
5. Scientists tailor cell surface targeting system to hit organelle ZIP codes
6. G proteins regulate remodelling of blood vessels
7. Salk study finds diabetes raises levels of proteins linked to Alzheimers features
8. Toward medicines that recruit the bodys natural disease-fighting proteins
9. Enzymes implicated in disease processes attack one another instead of harming body proteins
10. New regulatory mechanism discovered in cell system for eliminating unneeded proteins
11. Vanderbilt researchers find proteins may point way to new prostate cancer drug targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult ... If so, you may be interested in participating in a research study that ... research is to understand more about the relational aspects of adults who have gluten ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... announced that it is the first organization with pending recognition status from the ... Prevention Program (“DPP”) via group telehealth classes and live video conferencing. , ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of America ... as an interventional pain management physician. He brings a wealth of pain management ... headaches, and significant experience in spinal cord stimulation for chronic pain. , Dr. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning firm ... for efforts to educate the local population on cancer realities while attracting donations to ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed and ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy ... data on Cell-Ess® Universal Titer Boost at the 9 th ... August 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess ... ... Cell-Ess ...
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/15/2017)... N.C. , Aug. 15, 2017 AccuGenomics, ... NC , today announced that the company has ... the University of North Carolina at Chapel Hill and ... is designed to characterize and quantify HIV reservoir and ... after pharmacological intervention. The HIV Cure Center is a ...
Breaking Medicine Technology: